Saving changes...

Done

Error

Clinical Advances in Pulmonary Arterial Hypertension

Clinical Advances in Pulmonary Arterial Hypertension

Clinical Advances in Pulmonary Arterial Hypertension

National Association for Continuing Education
National Association for Continuing Education
on behalf of National Association for Continuing Education

$20.00 $ 20.00 $ 20.00

$20.00 $ 20.00 $ 20.00

$ 20.00 $ 20.00 $ 20.00
$ 20.00 $ 20.00 $ 20.00
Normal Price: $20.00 $20.00

Review:

Launch date: 15 Feb 2018
Expiry Date: 14 Jan 2019

Last updated: 22 Aug 2018

Reference: 187004

This course is no longer available

Exam is embedded in the course
No preview available
No Exam Available

Latest User Comments

I would like to...

Course Availability

This course is only available to trainees days after purchase. It would need to be repurchased by the trainee if not completed in the allotted time period. This course is no longer available. You will need to repurchase if you wish to take the course again.

Description

Welcome to the National Association for Continuing Education monograph from the NACE Clinical Updates for NPs and PAs 2017 conference.

Pulmonary arterial hypertension (PAH) is a subgroup of pulmonary hypertension (PH) - a chronic and progressive condition characterized by abnormally high pressure in the pulmonary vasculature. PAH has previously been considered a rare disease, but evidence suggests a prevalence of about 15-50 cases per million. In the United States, about 1,000 new cases of PAH are diagnosed each year while mortality and hospitalization rates for PH have been increasing.

Dyspnea with exertion is by far the most common presenting symptom of PAH, but this symptom is often mistakenly attributed to other causes such as deconditioning, obesity, asthma, or other known underlying pulmonary or cardiac disorders. In practice, early recognition of PAH remains a challenge because the condition does not become clinically manifest until pulmonary vascular disease is advanced. Expertise in the diagnosis and management of PAH is uncommon, and PAH is underdiagnosed and misdiagnosed.

Dramatic advances in the treatment of PAH have occurred over the past two decades, as demonstrated in multiple studies. Despite these advances, education and training of clinicians has lagged behind advances in the management of PAH.

This monograph will help primary care clinicians develop a greater awareness and comfort level with the identification, diagnosis and management of patients with PAH.

Objectives

Objective 1: Discuss the pathophysiology of pulmonary arterial hypertension (PAH).
After completing this program participants should be able to discuss the pathophysiology of pulmonary arterial hypertension (PAH).
Objective 2: Recognize signs and symptoms suggestive of PAH and the appropriate diagnostic strategy.
After completing this program participants should be able to recognize signs and symptoms suggestive of PAH and the appropriate diagnostic strategy.
Objective 3: Describe how to monitor patients with PAH for disease progression.
After completing this program participants should be able to describe how to monitor patients with PAH for disease progression.
Objective 4: Review current and emerging treatments for patients with PAH.
After completing this program participants should be able to review current and emerging treatments for patients with PAH.
National Association for Continuing Education

Author Information Play Video Bio

National Association for Continuing Education
on behalf of National Association for Continuing Education

The mission of the National Association for Continuing Education (NACE) is to offer continuing education opportunities to provide learners in the fields of medicine, behavioral health, education, and related disciplines, with the most up-to-date, science-based information that will enable them to increase their knowledge, competence, and professional performance to ultimately benefit their patients' health.

Current Accreditations

This course has been certified by or provided by the following Certified Organization/s:

  • Accreditation Council for Continuing Medical Education (ACCME)
  • 1.00 Credits
  • American Association of Nurse Practitioners (AANP)
  • 1.00 Hours -
    Exam Pass Rate: 70

Faculty and Disclosures

Additional Contributors

Course Directors
Gregg Sherman, MD
Chief Medical Officer, NACE
Plantation, FL

Deborah Paschal, CRNP
Philadelphia, PA

Medical Writer
Josh Kilbridge
Kilbride Associates Healthcare Communications
San Francisco, CA

Course Reviewer
Alexander Duarte, MD
Professor
Division of Pulmonary Critical Care & Sleep Medicine
Department of Internal Medicine
University of Texas Medical Branch
Galveston, TX

Conflicts Declared

Conflicts of Interest declaration by Author:

Policy on Faculty and Provider Disclosure: It is the policy of the National Association for Continuing Education to ensure fair balance, independence, objectivity and scientific rigor in all activities. All faculty participating in CME activities sponsored by the National Association for Continuing Education are required to present evidence-based data, identify and reference off-label product use and disclose all relevant financial relationships. Faculty disclosures are provided below.

Alexander Duarte, MD, Course Reviewer, has no relationships to disclose.

Gregg Sherman, MD, Course Director, has no relationships to disclose.

Josh Kilbridge, Medical Writer, has no relationships to disclose.

Harvey C. Parker, Ph.D., Activity Planning Committee, has no relationships to disclose.

Michelle Frisch, MPH, Activity Planning Committee, has no relationships to disclose.
Commercial Support
This educational activity is supported by an an educational grant from Actelion Pharmaceuticals US, Inc.

User Reviews (0)

Go Back

Loading...


Saving changes...

Done

Error